ENDRA Life Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its Q2 2021 financial results on August 12, 2021, following the market close. The management will host a conference call and webcast at 4:30 p.m. ET to discuss results and recent corporate updates. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue at a fraction of MRI costs, particularly for assessing liver conditions like NAFLD and NASH. The technology is compatible with numerous existing ultrasound systems.

Positive

• Innovative TAEUS technology targeting liver disease diagnostics.
• Potential to reduce diagnostic costs significantly.
• Strong market need for effective NAFLD and NASH diagnostics.

Negative

• None.

ANN ARBOR, MI / ACCESSWIRE / August 2, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2021 on Thursday, August 12, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Participation instructions are as follows:

Dial-in Numbers
International: 862-298-0970

Replay Dial-in Numbers
U.S./Canada: 877-481-4010

International: 919-882-2331

Replay Passcode: 42091

The telephone replay will be available through 4:30 p.m. Eastern time on August 19, 2021

Webcast
A live audio webcast will be available through the Events & Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 60 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS^® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visitwww.endrainc.com.

Company Contact:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/657939/ENDRA-Life-Sciences-to-Report-Second-Quarter-2021-Financial-Results-on-August-12-2021

FAQ

When will ENDRA Life Sciences report its Q2 2021 financial results?

ENDRA Life Sciences will report its Q2 2021 financial results on August 12, 2021.

What is the focus of ENDRA Life Sciences' TAEUS technology?

TAEUS technology focuses on visualizing liver tissue to assess conditions like NAFLD and NASH.

What time is the conference call for ENDRA's Q2 2021 results?

The conference call is scheduled for 4:30 p.m. Eastern Time on August 12, 2021.

How can I access the webcast of ENDRA Life Sciences' results?

The webcast can be accessed through the Events & Presentations page on ENDRA's investor website.

What is the cost benefit of ENDRA's TAEUS technology compared to MRI?

TAEUS is designed to visualize tissue at 1/50th the cost of MRI.